While classical markers, such as HepPar1, Arg-1, and GPC3, remain foundational for distinguishing HCC from benign lesions and metastatic tumors, their limitations in specificity and sensitivity underscore the need for combinatorial approaches. This evidence concerns the gene ARG1 and metastatic neoplasm.